Alva, Manuel; Lopez-Tarruella, Sara; Zielinski, Christoph; Ruiz-Borrego, Manuel; Turner, Nicholas; Ciruelos, Eva; Munoz, Montserrat; Bermejo, Begona; Margeli, Mireia; Anton, Antonio; Kahan, Zsuzsanna; Csoszi, Tibor; Casas, Maribel; Murillo, Laura; Murillo, Serafin Morales; Alba, Emilio; Yam, Einav Nili-Gal; Guerrero, Angel; Calvo, Lourdes; de la Haba-Rodriguez, Juan; Ramos, Manuel; Alvarez, Isabel; Garcia-Palomo, Andres; Koehler, Maria; Garcia-Saenz, Jose Angel; Chacon, J. Ignacio; Swift, Claire; Thallinger, Christiane; Gil-Gil, Miguel; Martin, Miguel

Real-World Outcomes of Patients Receiving First-line Palbociclib Plus Endocrine Therapy in Spain: Subgroup Analysis Based on Tumor Grade, Progesterone Receptor, Ki-67 and Histological Subtype from PALBOSPAIN Study

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Guerrero-Zotano, Angel; Benelli, Matteo; Irrthum, Alexandre; Cameron, David; Ferrando, Lorenzo; Romagnoli, Dario; Paoli, Marta; Llinas, Arnau; Dadiani, Maya; Fimereli, Danai; Oliveira, Mafalda; Caballero, Carmela; Crestani, Thayane; Agostinetto, Elisa; Martins-Branco, Diogo; Hilbers, Florentine; Gal-Yam, Einav; Balic, Marija; Cardoso, Fatima; Reis-Filho, Jorge; Sotiriou, Christos; Curigliano, Giuseppe; Linderholm, Barbro; de Azambuja, Evandro; Knox, Susan; Rotaru, Cristina; Ciruelos, Eva; Davidson, Nancy E.; Viale, Giuseppe; Taylor, Donatienne; Canon, Jean-Luc; Calvo, Lourdes; Albanell, Joan; Colleoni, Marco; Duhem, Caroline; Harbeck, Nadia; Herremans, Catherine; Loibl, Sibylle; Marreaud, Sandrine; Scheepers, Elsemieke; Raimbault, Alice; Goulioti, Theodora; Vingiani, Andrea; Biagioni, Chiara; Vosberg, Sebastian; Zoppoli, Gabriele; Seoane, Jose; Venet, David; Aftimos, Philippe; Piccart, Martine

Real-world efficacy of dual HER2-blockade in combination with anthracyclinecontaining and anthracycline-free neoadjuvant treatment in early breast cancer (BC)

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2024-04-044

Gebhart, Geraldine; Keyaerts, Marleen; Guiot, Thomas; Flamen, Patrick; Ruiz-Borrego, Manuel; Stradella, Agostina; Bermejo, Begona; Escriva-de-Romani, Santiago; Martinez, Lourdes Calvo; Ribelles, Nuria; Fernandez-Abad, Maria; Albacar, Cinta; Colleoni, Marco; Garrigos, Laia; de Frutos, Manuel Atienza; Dalenc, Florence; Prat, Aleix; Marme, Frederik; Schmid, Peter; Kerrou, Khaldoun; Braga, Sofia; Gener, Petra; Sampayo-Cordero, Miguel; Cortes, Javier; Perez-Garcia, Jose Manuel; Llombart-Cussac, Antonio

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

LANCET

IF88.5

2024-04-0116

PRE

Perez-Garcia, Jose Manuel; Cortes, Javier; Ruiz-Borrego, Manuel; Colleoni, Marco; Stradella, Agostina; Bermejo, Begona; Dalenc, Florence; Escriva-de-Romani, Santiago; Martinez, Lourdes Calvo; Ribelles, Nuria; Marme, Frederik; Cortes, Alfonso; Albacar, Cinta; Gebhart, Geraldine; Prat, Aleix; Kerrou, Khaldoun; Schmid, Peter; Braga, Sofia; Di Cosimo, Serena; Gion, Maria; Antonarelli, Gabriele; Popa, Crina; Szostak, Emilia; Alcala-Lopez, Daniel; Gener, Petra; Rodriguez-Morato, Jose; Mina, Leonardo; Sampayo-Cordero, Miguel; Llombart-Cussac, Antonio

NEOADYUVANT TREATMENT IN THE COVID ERA

CANCER RESEARCH

IF16.6

2023-03-010

PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS

CANCER RESEARCH

IF16.6

2023-03-012

PRE

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

PEARL研究中激素受体阳性、HER2-negative转移性乳腺癌绝经后患者接受palbociclib联合内分泌治疗与卡培他滨治疗的总生存率比较

EUROPEAN JOURNAL OF CANCER

IF7.1

2022-06-0112

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-02-1110

OAAI

Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

palbociclib联合内分泌治疗与卡培他滨治疗绝经后激素受体阳性转移性乳腺癌患者的健康相关生活质量的原始研究: PEARL研究中患者报告的结果

EUROPEAN JOURNAL OF CANCER

IF7.1

2021-10-0117

Kahan, Zsuzsanna; Gil-Gil, Miguel; Ruiz-Borrego, Manuel; Carrasco, Eva; Ciruelos, Eva; Munoz, Montserrat; Bermejo, Begona; Margeli, Mireia; Anton, Antonio; Casas, Maribel; Csoszi, Tibor; Murillo, Laura; Morales, Serafin; Calvo, Lourdes; Lang, Istvan; Alba, Emilio; de la Haba-Rodriguez, Juan; Ramos, Manuel; Alvarez Lopez, Isabel; Gal-Yam, Einav; Garcia-Palomo, Andres; Alvarez, Elena; Gonzalez-Santiago, Santiago; Rodriguez, Cesar A.; Servitja, Sonia; Corsaro, Massimo; Rodrigalvarez, Graciela; Zielinski, Christoph; Martin, Miguel

Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

ANNALS OF ONCOLOGY

IF65.4

2021-09-013

OAAI

Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer? (May, 10.1007/s00428-021-03104-7, 2021)

VIRCHOWS ARCHIV

IF3.1

2021-06-120

OAAI

Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

VIRCHOWS ARCHIV